Alnylam Pharmaceuticals is trading on the Nasdaq stock exchange and is receiving analyst coverage and target price reports.
2 reports, 2 independent
Updated Jul 30
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals is trading on the Nasdaq stock exchange and is receiving analyst coverage and target price reports.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Alnylam lowered its TTR revenue guidance while trading on Nasdaq.1 source
The company is trading on Nasdaq and has received analyst coverage.1 source
Keep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
-
Nasdaq
American fully electronic stock exchange
Related events
- BioPharma stock was traded on the NASDAQ stock exchange on July 30, 2026, with its performance tracked by financial blogs.
- Arrive AI traded on the Nasdaq stock exchange, with its performance covered by financial blog MarketBeat.
- Odyssey Therapeutics, Inc. shares are being traded on the Nasdaq exchange.
- Royal Bank of Canada raised its position in Bright Minds Biosciences Inc., a company trading on the Nasdaq exchange.
- Corvus Pharmaceuticals began trading on the Nasdaq exchange on August 1, 2026.